These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12495475)

  • 1. Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro.
    Koshida S; Narita T; Kato H; Yoshida S; Taga T; Ohta S; Takeuchi Y
    Jpn J Cancer Res; 2002 Dec; 93(12):1351-7. PubMed ID: 12495475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.
    Müller V; Jensen EV; Knabbe C
    Cancer Res; 1998 Jan; 58(2):263-7. PubMed ID: 9443403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-estrogens induce apoptosis of multiple myeloma cells.
    Treon SP; Teoh G; Urashima M; Ogata A; Chauhan D; Webb IJ; Anderson KC
    Blood; 1998 Sep; 92(5):1749-57. PubMed ID: 9716605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
    Obrero M; Yu DV; Shapiro DJ
    J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.
    Catherino WH; Wolf DM; Jordan VC
    Mol Endocrinol; 1995 Aug; 9(8):1053-63. PubMed ID: 7476979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells.
    MacGregor Schafer J; Liu H; Levenson AS; Horiguchi J; Chen Z; Jordan VC
    J Steroid Biochem Mol Biol; 2001 Jul; 78(1):41-50. PubMed ID: 11530283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in morphology and cytoskeleton of MCF-7 and MX-1 cells after therapy with OH-tamoxifen and the pure estrogen antagonist ZM 182780. An immunofluorescence and scanning electron microscopic study.
    Ehlers EM; Schubert C
    Ann Anat; 1999 May; 181(3):231-6. PubMed ID: 10363104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
    Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
    Lau KM; LaSpina M; Long J; Ho SM
    Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tamoxifen ligands on estrogen receptor interaction with estrogen response elements.
    Klinge CM; Studinski-Jones AL; Kulakosky PC; Bambara RA; Hilf R
    Mol Cell Endocrinol; 1998 Aug; 143(1-2):79-90. PubMed ID: 9806352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
    Journe F; Chaboteaux C; Magne N; Duvillier H; Laurent G; Body JJ
    Breast Cancer Res; 2006; 8(1):R2. PubMed ID: 16417650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study on the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line.
    Ercoli A; Scambia G; Fattorossi A; Raspaglio G; Battaglia A; Cicchillitti L; Malorni W; Rainaldi G; Benedetti Panici P; Mancuso S
    Int J Cancer; 1998 Mar; 76(1):47-54. PubMed ID: 9533761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells.
    Gong Y; Ballejo G; Murphy LC; Murphy LJ
    Cancer Res; 1992 Apr; 52(7):1704-9. PubMed ID: 1551100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
    Castro-Rivera E; Safe S
    J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor.
    Zajchowski DA; Sager R; Webster L
    Cancer Res; 1993 Oct; 53(20):5004-11. PubMed ID: 8402691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells.
    Levenson AS; Svoboda KM; Kwaan HC; Jordan VC
    Cancer Lett; 1998 Mar; 125(1-2):215-20. PubMed ID: 9566718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness.
    Thompson EW; Katz D; Shima TB; Wakeling AE; Lippman ME; Dickson RB
    Cancer Res; 1989 Dec; 49(24 Pt 1):6929-34. PubMed ID: 2582435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.